PL2813239T3 - Kompozycja farmaceutyczna zawierająca neurotoksynę botulinową A2 - Google Patents

Kompozycja farmaceutyczna zawierająca neurotoksynę botulinową A2

Info

Publication number
PL2813239T3
PL2813239T3 PL14180875T PL14180875T PL2813239T3 PL 2813239 T3 PL2813239 T3 PL 2813239T3 PL 14180875 T PL14180875 T PL 14180875T PL 14180875 T PL14180875 T PL 14180875T PL 2813239 T3 PL2813239 T3 PL 2813239T3
Authority
PL
Poland
Prior art keywords
pharmaceutical composition
composition containing
botulinum neurotoxin
containing botulinum
neurotoxin
Prior art date
Application number
PL14180875T
Other languages
English (en)
Inventor
Naveed Panjwani
Paul Webb
Andrew Pickett
Original Assignee
Ipsen Biopharm Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35063257&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2813239(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0417367A external-priority patent/GB2416692A/en
Priority claimed from GB0421288A external-priority patent/GB2418358A/en
Priority claimed from GB0421290A external-priority patent/GB2418359A/en
Priority claimed from GB0423953A external-priority patent/GB2419527A/en
Priority claimed from GB0423952A external-priority patent/GB2419526A/en
Application filed by Ipsen Biopharm Limited filed Critical Ipsen Biopharm Limited
Publication of PL2813239T3 publication Critical patent/PL2813239T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Birds (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
PL14180875T 2004-08-04 2005-08-03 Kompozycja farmaceutyczna zawierająca neurotoksynę botulinową A2 PL2813239T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0417367A GB2416692A (en) 2004-08-04 2004-08-04 Pharmaceutical composition containing botulinum neurotoxin
GB0421288A GB2418358A (en) 2004-09-24 2004-09-24 Pharmaceutical composition comprising botulinum neurotoxin
GB0421290A GB2418359A (en) 2004-09-24 2004-09-24 Pharmaceutical composition comprising botulinum neurotoxin
GB0423953A GB2419527A (en) 2004-10-28 2004-10-28 Pharmaceutical composition containing botulinum neurotoxin
GB0423952A GB2419526A (en) 2004-10-28 2004-10-28 Pharmaceutical composition containing botulinum neurotoxin
EP14180875.8A EP2813239B1 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin A2

Publications (1)

Publication Number Publication Date
PL2813239T3 true PL2813239T3 (pl) 2017-11-30

Family

ID=35063257

Family Applications (2)

Application Number Title Priority Date Filing Date
PL05767871T PL1776137T3 (pl) 2004-08-04 2005-08-03 Kompozycja farmaceutyczna zawierająca neurotoksynę botulinową
PL14180875T PL2813239T3 (pl) 2004-08-04 2005-08-03 Kompozycja farmaceutyczna zawierająca neurotoksynę botulinową A2

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL05767871T PL1776137T3 (pl) 2004-08-04 2005-08-03 Kompozycja farmaceutyczna zawierająca neurotoksynę botulinową

Country Status (9)

Country Link
US (2) US20080069841A1 (pl)
EP (3) EP2813239B1 (pl)
DK (2) DK2813239T3 (pl)
ES (2) ES2526912T3 (pl)
HU (1) HUE032950T2 (pl)
PL (2) PL1776137T3 (pl)
PT (2) PT1776137E (pl)
TR (1) TR201708749T4 (pl)
WO (1) WO2006013357A1 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2416122A (en) * 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
US8168206B1 (en) * 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
JPWO2010013494A1 (ja) * 2008-07-31 2012-01-05 一般財団法人化学及血清療法研究所 軸索輸送されないボツリヌス神経毒素製剤を含有する医薬組成物およびその利用
US8512715B2 (en) 2008-08-14 2013-08-20 The Cleveland Clinic Foundation Apparatus and method for treating a neuromuscular defect
US9204925B2 (en) 2008-08-14 2015-12-08 The Cleveland Clinic Foundation Apparatus and method for treating a neuromuscular defect
US8506970B2 (en) * 2008-10-14 2013-08-13 Dt Scimed, Llc Dose and localization of botulinum toxins in skin and muscle
DK2379104T3 (en) 2008-12-31 2018-04-30 Revance Therapeutics Inc Injectable botulinum toxin formulations
US9340587B2 (en) 2009-06-25 2016-05-17 Revance Therapeutics, Inc. Albumin-free botulinum toxin formulations
ES2643507T3 (es) * 2012-03-12 2017-11-23 William J. Binder Tratamiento de las cefaleas por migraña con la neurotoxina presináptica
MX370929B (es) 2012-10-28 2020-01-08 Revance Therapeutics Inc Composiciones y usos de las mismas para el tratamiento seguro de la rinitis.
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
SI3432916T1 (sl) 2016-09-13 2020-01-31 Allergan, Inc. Stabilizirani ne-protein klostridijski toksin sestavki
US20240024220A1 (en) * 2019-05-11 2024-01-25 Youngsuk Yi Neurotoxin compositions and methods
EP4161540A4 (en) 2020-06-03 2024-07-10 Miotox, LLC Zonal and targeted methods and uses for treating a migraine disorder
KR102729701B1 (ko) * 2021-06-18 2024-11-14 충북대학교 산학협력단 불멸화 줄기세포의 엑소좀 풍부 배양액 및 보툴리눔 독소를 포함하는 기능성 조성물
WO2025155124A1 (ko) * 2024-01-18 2025-07-24 (주)메디톡스 비-복합체 보툴리눔 독소 조성물의 빠른 효력 발현 효과 및 이와 관련된 방법

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2630115B1 (fr) * 1988-04-14 1994-10-28 Merieux Inst Procede de stabilisation des solutions d'albumine humaine et solution obtenue
DK0682524T3 (da) * 1993-02-02 2002-01-28 Xoma Technology Ltd Farmaceutiske præparater indeholdende et baktericid/permeabilitetsforøgende protein og et afspændingsmiddel
US5756468A (en) 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
EP1949909B1 (en) * 1997-07-15 2014-01-08 The Regents of the University of Colorado, a body corporate Use of Botulinum Toxin Therapy for Treatment of Urge Type Dysfunction
US6265379B1 (en) * 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
ES2368061T3 (es) 2000-02-08 2011-11-14 Allergan, Inc. Composiciones farmacéuticas de toxina botulínica.
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US6299893B1 (en) * 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US6827931B1 (en) 2000-10-20 2004-12-07 Allergan, Inc. Method for treating endocrine disorders
AU2002320127A1 (en) * 2001-06-21 2003-01-08 Surromed, Inc. Covalent coupling of botulinum toxin with polyethylene glycol
JPWO2003082315A1 (ja) 2002-03-29 2005-07-28 財団法人化学及血清療法研究所 筋緊張亢進疾患治療剤
GB2398636A (en) 2003-02-21 2004-08-25 Ipsen Ltd Method for determining the quantity of pre-synaptic neuromuscular blocking substance contained in a sample
EP1570855A1 (fr) * 2004-03-04 2005-09-07 Claude Le Louarn Utilisation de toxine botulique pour préparer un médicament destiné à prévenir la pousse de poils

Also Published As

Publication number Publication date
DK1776137T3 (en) 2015-01-05
EP3210620A1 (en) 2017-08-30
US20080069841A1 (en) 2008-03-20
EP2813239B1 (en) 2017-03-22
ES2627627T3 (es) 2017-07-28
EP2813239A1 (en) 2014-12-17
DK2813239T3 (en) 2017-06-06
EP1776137B1 (en) 2014-11-26
PL1776137T3 (pl) 2015-03-31
TR201708749T4 (tr) 2018-03-21
PT2813239T (pt) 2017-06-09
PT1776137E (pt) 2014-12-31
EP1776137A1 (en) 2007-04-25
US20100184689A1 (en) 2010-07-22
HUE032950T2 (en) 2017-11-28
WO2006013357A1 (en) 2006-02-09
ES2526912T3 (es) 2015-01-16

Similar Documents

Publication Publication Date Title
GB0415491D0 (en) Pharmaceutical composition containing botulinum neurotoxin
IL225848A0 (en) A medical preparation containing botulinum neurotoxin
PT2813239T (pt) Composição farmacêutica contendo a neurotoxina botulínica a2
IL177480A0 (en) Pharmaceutical composition
IL186336A0 (en) Pharmaceutical composition
ZA200606154B (en) Pharmaceutical composition comprising pimobendan
GB0417367D0 (en) Pharmaceutical composition containing botulinum neurotoxin
HU0401177D0 (en) Pharmaceutical composition
GB0423952D0 (en) Pharmaceutical composition containing botulinum neurotoxin
GB2411355B (en) Pharmaceutical composition
GB0423953D0 (en) Pharmaceutical composition containing botulinum neurotoxin
GB0425255D0 (en) Pharmaceutical composition
ZA200701932B (en) Pharmaceutical composition
GB0421288D0 (en) Pharmaceutical composition containing botulinum neurotoxin
GB0423950D0 (en) Pharmaceutical composition containing botulinum neurotoxin
ZA200808768B (en) Pharmaceutical composition containing the NMB0606 protein
ZA200701931B (en) Pharmaceutical composition
GB0421290D0 (en) Pharmaceutical composition containing botulinum neurotoxin
ZA200805355B (en) Pharmaceutical compositions containing protein NMA0939
GB0402799D0 (en) Pharmaceutical composition
GB0425256D0 (en) Pharmaceutical composition
GB0425259D0 (en) Pharmaceutical composition
GB0518166D0 (en) Pharmaceutical composition
GB0511801D0 (en) Pharmaceutical composition
GB0504276D0 (en) Pharmaceutical composition